Mafalda Oliveira

38PUBLICATIONS
360CO-AUTHORS
Liquid biopsiesMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Sep 29, 2026
Peripheral Blood as the Sole Source for Cancer Neoantigen and Reactive T-Cell Discovery.

|Jul 13, 2026
Application of a Translational Research Platform to Unveil Efficacy Signals and Mechanisms of Resistance of FGFR Inhibitors in Multiple FGFR-Altered Solid Tumors.

|May 19, 2026
Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

|Feb 16, 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).

Tomás Pascual, Maria Vidal, Juan M Cejalvo

|Feb 03, 2026
PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

Rosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum

|Jan 22, 2026
Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual

Pageof 7

Frequent Collaborators

16 joint publications

Cristina Saura Manich

12 joint publications

Aleix Prat

10 joint publications

Tomás Pascual

10 joint publications

Paolo Nuciforo